# US 2017/0247387 A1 · Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0247387 A1
- Document ID: US20170247387A1
- Status: Published application
- Kind: A1
- Application number: 15/328,428
- Filed: 2015-07-24
- Published: 2017-08-31
- Earliest claimed: 2014-07-25
- Assignees: Northeastern University
- Applicants: Northeastern University
- Inventors: Alexandros Makriyannis; Vidyanand G Shukla; Shakiru O Alapafuja
- Web page: https://patentgrep.com/patent/US20170247387A1

## CPC

- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 211/16: with acylated ring nitrogen atom
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D 211/54: Sulfur atoms
- C07D 213/64: attached in position 2 or 6
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 213/84: Nitriles
- C07D 213/85: in position 3
- C07D 215/04: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D 215/12: with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D 233/61: with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
- C07D 241/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 257/04: Five-membered rings
- C07D 295/14: substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 295/195: Radicals derived from nitrogen analogues of carboxylic acids
- C07D 295/26: Sulfur atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/14: containing three or more hetero rings
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 411/12: linked by a chain containing hetero atoms as chain links
- C07D 471/08: Bridged systems
- C07D 487/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed are compounds that may be used to inhibit the action of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH/MAGL.

## Claims

### Claim 1

A compound of formula IA
wherein
X=CH, N;
R1=—H, -alkyl;
R2=—H, -alkyl, where alkyl is saturated C1-10 hydrocarbon, which may be straight or branched chain;
n=0-3;
Ai is selected from aryl, heteroaryl, benzhydryl, fluorenyl, aryl(aryl)methyl,
aryl(phenyl)methyl, aryl(alkyl)methyl, aryl(cycloalkyl)methyl and each aryl, heteroaryl or fluorenyl group may be unsubstituted, mono or di-substituted with moieties selected from:
—NO2, —CN, —OH, -alkyl, —O-alkyl, -halogen, —CF3, —OCF3, —S-alkyl, —OPh, -Ph-S(0)-alkyl, S02-alkyl, —C02-alkyl, —COOH, —NHR3, —NR3R4, —NR3S02R4, —N02, —CN, —CONR3R4;
morpholino; thiomorpholino, 1,1-dioxothiomorpholine, oxothiomorpholino,
R3 and R4 are independently selected from —H or -alkyl, cycloalkyl; and
R6 is selected from H, —CN, —OH, —OMe, —CF3, —OCF3, —OBn, —CONH2, —S02NH2, —COOH.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein
X=N and n=0-1.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The compound according to claim 1 wherein the compound is selected from the group consisting of:
(5)-N-(3′-carbamoyl-[1,-biphenyl]-3-yl)-3-methyl-4-(quinolin-2-ylmethyl) piperazine-1-carboxamide;
(5̂-N-(3′-cyano-[l,-biphenyl]-3-yl)-2-methyl-4-(3-phenoxybenzyl)piperazine-1-carboxamide;
(S)—N-(3′-carbamoyl-[1,1′-biphenyl]-3-yl)-2-methyl-4-(3-phenoxybenzyl)piperazine-1-carboxamide;
N-(3′-carbamoyl-[1,-biphenyl]-3-yl)-4-(quinolin-3-ylmethyl)piperazine-1-carboxamide;
N-(3′-carbamoyl-[1,1′-biphenyl]-3-yl)-4-phenylpiperidine-1-carboxamide;
N-(3′-carbamoyl-[1,1′-biphenyl]-3-yl)-4-(9H-fluoren-9-yl)piperazine-1-carboxamide
N-(3′-carbamoyl-[1,1′-biphenyl]-3-yl)-4-(pyridin-2-yl)piperazine-1-carboxamide
4-([1,1′-biphenyl]-4-ylmethyl)-N-(3′-carbamoyl-[1,1′-biphenyl]-3-yl)piperazine-1-carboxamide
N-(3′-carbamoyl-[1,1′-biphenyl]-3-yl)-4-phenylpiperazine-1-carboxamide
N-(3′-carbamoyl-[1,-biphenyl]-3-yl)-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide
N-(3′-cyano-[1,1′-biphenyl]-3-yl)-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide
4 ([1,1′-biphenyl]-3-ylmethyl)-N-(3′-cyano-[1,1′-biphenyl]-3-yl)piperazine-1-carboxamide; and
N-(3′-carbamoyl-[1,1′-biphenyl]-3-yl)-4-(3-phenoxybenzyl)piperazine-1-carboxamide.

### Claim 6

A compound of formula IB
wherein
R1=—H, -alkyl;
R2=—H, -alkyl, where alkyl is saturated C1-10 hydrocarbon, which may be straight or branched chain;
Li is selected from a double bond, —(CH2)n—, -0-, —CH═CH—, —CONH—, —S—, —S(=0)-, —S02—, —NH—, and —NRi-, where n=0-6;
Ai is selected from aryl, heteroaryl, benzhydryl, fluorenyl, aryl(aryl)methyl,
aryl(phenyl)methyl, aryl(alkyl)methyl, aryl(cycloalkyl)methyl and each aryl, heteroaryl or fluorenyl group may be unsubstituted, mono or di-substituted with following moieties;
—N02, —CN, —OH, -alkyl, —O-alkyl, -halogen, —CF3, —OCF3, —S-alkyl, —OPh, -Ph-S(0)-alkyl, —S02-alkyl, —C02-alkyl, —COOH, —NHR3, —NR3P, —NR3S02R4, —N02, —CN, —CONR3R4;
morpholino; thiomorpholino, 1,1-dioxothiomorpholine, and oxothiomorpholino,
R3 and R4 are independently selected from —H, -alkyl, and cycloalkyl;
R5 is selected from H, OH, and halogen; and
Rs is selected from H, —CN, —OH, —OMe, —CF3, —OCF3, —OBn, —CONH2, —S02NH2, and —COOH.

### Claim 7 (depends on 6)

The compound according to claim 6 wherein
Li is selected from a double bond and —(CH2)n-; and
n=0-1.

### Claim 8

(canceled)

### Claim 9 (depends on 6)

The compound according to claim 6 wherein:
Ai is selected from the group consisting of: phenyl, benzyl and benzhydryl.

### Claim 10 (depends on 6)

The compound according to claim 6 wherein the compound is selected from the group consisting of:
5-Cyano-2-fluorophenyl 4-benzylpiperidine-1-carboxylate,
3-Cyanophenyl 4-benzhydrylpiperidine-1-carboxylate,
3-cyanophenyl 4-(diphenylmethylene)piperidine-1-carboxylate, and
3-cyanophenyl 4-benzylpiperidine-1-carboxylate.

### Claim 11

A compound of Formula II
wherein
M=0 or S;
Z=O, NH, or none; when Z=none B2 is directly attached to C=M;
n=1-2;
L2 is selected from
—O—, —CH═CH—, —CONH,
—S—, —S(O)—, SO2, —NH—, n=0-2;
A2 is selected from aryl, heteroaryl, fluoren-9-yl, aryl(alkyl)methyl, aryl(cycloalkyl)methyl, heteroaryl(alkyl)methyl, or heteroaryl(cycloalkyl)methyl and each aryl, heteroaryl or fluore-9-nyl group may be unsubstituted, or substituted with one or two moieties as defined below; —OH, -alkyl, —O-alkyl, -halogen, —CF3, —OCF3, —S-alkyl, —OPh, -Ph-S(0)-alkyl, —S02-alkyl, —C02-alkyl, —COOH, —NHR, —NR3P, —NR3S02R4, —N02, —CN, —CONR3R4, -alkynyl, morpholino, thiomorpholino, 1,1-dioxothiomorpholine, 1-oxothiomorpholino;
R3 and R4 are independently selected from —H; -alkyl, and cycloalkyl;
B2 is selected from aryl and heteroaryl groups, and each aryl or heteroaryl group may be unsubstituted or substituted with one or two moieties as defined below:
-halogen —NO2, —CN, —OH, —NH2, —CONH2, —O-aryl, —CF3, —OCF3, —OCF2H, —SCF3;
B3 is selected from
wherein Wi is either CH or N;
W2 is selected from CH2, O, S02, CHAr, and NAr;
Ar is aryl or heteroaryl containing 1 to 3 heteroatoms;
R5 is selected from —H, -halogen —NO2, —CN, —OH, -Ph, —COOMe; —NH2, —CONH2, —O-aryl, -CF3, —OCF3, —OCF2H, and —SCF3;
R6 is selected from monocyclic heteroaryl ring containing 1 to 3 heteroatoms, and the heteroaryl ring is optionally substituted with one or two groups, as defined below:
—CN, —OH, —OMe, —CF3, —OCF3, —OBn, —CONH2, —S02NH2, —COOH -halogen, or
wherein M is selected from O and S.

### Claim 12 (depends on 11)

The compound of claim 11 wherein
L2 is selected from —(CH2), 0-, O, —CH═CH—, —CONH—S—, —S(O)—, S02, —NH—,
and n=0-1.

### Claim 13 (depends on 11)

The compound according to claim 11 wherein
M=0;
A2 is selected from aryl, heteroaryl, and each aryl, heteroaryl group may be unsubstituted, or substituted with one or two moieties as defined below:
-halogen;
B2 is selected from aryl or heteroaryl groups, and each aryl or heteroaryl group may be unsubstituted or substituted with one or two moieties as defined below:
-halogen —CN, —CONH2, or
B2 is selected from
R5 is selected from —H, -Ph, —COOMe;
R6 is selected from monocyclic heteroaryl ring containing 1 to 3 heteroatoms, and the heteroaryl ring can be substituted with one or two halogen groups.

### Claim 14 (depends on 11)

The compound according to claim 11, wherein said compound is selected from the group consisting of:
3-Cyanophenyl 3-(4-chlorobenzyloxy)azetidine-1-carboxylate,
3-(Trifluoromethyl)phenyl 3-(4-chlorobenzyloxy)azetidine-1-carboxylate,
3-Bromophenyl 3-(4-chlorobenzyloxy)azetidine-1-carboxylate,
3-Carbamoylphenyl 3-(4-chlorobenzyloxy)azetidine-1-carboxylate,
3-Methoxyphenyl 3-(4-Bromobenzyloxy)azetidine-1-carboxylate,
2,4-Dichlorophenyl 3-(4-chlorobenzyloxy)azetidine-1-carboxylate,
3-(Pyridin-3-yl)phenyl 3-(4-chlorobenzyloxy)azetidine-1-carboxylate,
3-(4-Chlorobenzyloxy)-N-phenylazetidine-1-carboxamide,
3-(4-Bromobenzyloxy)-N-(pyridin-3-yl)azetidine-1-carboxamide,
1H Benzo[d]imidazol-1-yl)(3-(4-phenylpiperidin-1-yl)azetidin-1-yl)methanone,
3-(4-Benzylpiperidine)azetidin-1-yl)(4-phenyl[lHJ imizadol-1-yl)methanone,
4-Phenyl-1H-imidazol-1-yl)(3-(4-phenylpiperidin-1-yl)azetidin-1-yl)methanone,
3-(4-Bromobenzyloxy)azetidin-1-yl)(4-phenyl-1H-imidazol-1-yl)methanone,
1H-Benzo[d]imidazol-1-yl)(3-(4-Bromobenzyloxy)azetidin-1-yl)methanone,
3-(4-Bromobenzyloxy)azetidin-1-yl] (piperidin-1-yl)methanone,
(3-(4-Phenylpiperidin-1-yl)azetidin-1-yl)(1H-pyrazol-1-yl)methanone,
3-(4 Phenylpiperidin-1-yl)azetidin-1-yl)(\H-1,2,4-triazol-1-yl)methanone, and
3-(4-Bromophenylthio)azetidin-1-yl)(\H-1,2,4-triazol-1-yl)methanone.

### Claim 15

A compound of Formula III
wherein
X=CH or N;
M=0 or S;
Z=O, NH, or none; when Z=none B3 is directly attached to C=M;
n=1-3
L3 is selected from —(CH2), -j-0(CH2)n-, —C(═O)— when X is N, or from —(CH2),0-, —0-, —CH═CH—, —CONH—, —NH—, —NRi- when X is CH, where n=0-3;
A3 is selected from aryl, heteroaryl, fluoren-9-yl, and each aryl, heteroaryl or fluoren-9-yl group may be unsubstituted, or substituted with one or two moieties as defined below;
-halogen —N02, —CN, —OH, —NH2, —CONH2, —C02Me; -alkyl, -Oalkyl, -halogen, —CF3, —OCF3, —Salkyl, —OCH2Ph, -Ph, —S(0)-alkyl, —S02-alkyl, —C02-alkyl, —COOH, —NHR3, —NR3P, —NR3S02P, —N02, —CN, —CONR3R4; morpholino; thiomorpholino, 1,1-dioxothiomorpholine, oxothiomorpholino;
R3 and R4 are independently selected from —H or -alkyl, cycloalkyl;
B3 can be selected from aryl or heteroaryl groups, and each aryl or heteroaryl group may be unsubstituted or substituted with one or two moieties as defined below:
-halogen, —CN, —OH, —NH2, —C02Me, —CONH2, —OMe; or
B3 is also selected from
wherein Wi is either CH or N;
Ar can be aryl or heteroaryl containing 1 to 3 heteroatoms;
R5 is selected from —H, -halogen, —CN, —OH, —NH2, —C02Me, —CONH2, —OMe;
is selected from monocyclic heteroaryl ring containing 1 to 3 heteroatoms, and the heteroaryl ring can be substituted with one or two groups as defined below,
—CN, —OH, OMe, CF3, —OCH2Ph, —CONH2, —S02NH2, —COOH, halogen or
wherein M is selected from O and S.

### Claim 16 (depends on 15)

The compound according to claim 15 wherein
X=CH or N;
M=0 or S;
Z=O, NH, or none; when Z=none B3 is directly attached to C=M;
n=1-3
L3 is selected from —(CH2)n, -; -0(CH2)n-, or —C(═O)— when X is N, or L3 is selected from —(CH2)nO—, —O—, —CH═CH—, —CONH—, —NH—, —NRi when X is CH, where n=0-2; A3 is selected from aryl, heteroaryl, fluoren-9-yl, and each aryl, heteroaryl group may be unsubstituted, or substituted with one or two moieties as defined below;
-halogen, —N02, —CN, —OH, —NH2, —CONH2, —C02Me; -alkyl, -Oalkyl, -halogen, —CF3, —OCF3 Salkyl, —OCH2Ph, -Ph, —S(O)alkyl, —S02-alkyl, —C02-alkyl, —COOH, —NHR3, —NR3R4, —NR3S02R4, —N02, —CN, —CONR3R4; morpholino; thiomorpholino, 1,1-dioxothiomorpholine, oxothiomorpholino;
R3 and R4 are independently selected from —H or -alkyl, cycloalkyl;
B3 is selected from aryl or heteroaryl groups, and each aryl or heteroaryl group may be unsubstituted or substituted with one or two moieties as defined below:
-halogen, —CN, —OH, _C02Me, —CONH2; or
B3 is selected from
wherein Wi is either CH or N;
Ar is aryl or heteroaryl containing 1 to 3 heteroatoms;
R5 is selected from —H, -halogen, —CN, —OH, —NH2, —C02Me, —CONH2, —OMe;
R6 is selected from monocyclic heteroaryl ring containing 1 to 3 heteroatoms, and the heteroaryl ring can be substituted with one or two groups as defined below,
—CN, —OH, —OMe, —CF3, OCF3, —OBn, —CONH2, —S02NH2, —COOH, halogen or
wherein M is O or S.

### Claim 17 (depends on 16)

The compound according to claim 16 wherein
X=N;
M=O;
Z=O, NH or none; when Z=none B3 is directly attached to C=M;
n=1;
L3 is selected from is selected from —(CH2)n where n is 0 or 1;
A3 is selected from aryl, heteroaryl, fluorenyl, and each aryl, heteroaryl group may be unsubstituted, substituted with one or two moieties as defined below;
-halogen, —OCH2Ph, -Ph;
B3 is selected from aryl and heteroaryl groups, and each aryl or heteroaryl group may be unsubstituted or substituted with moieties as defined below:
—CN, _C02Me, —CONH2; or
B3 is
and
R6 is selected from halogen and phenyl.

### Claim 18 (depends on 15)

The compound according to claim 15, wherein said compound is selected from the group consisting of:
(1S,4S)—N-(3′-carbamoyl-[1,1′-bipheny-3-yl)-5-quinolin-1-ylmethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxamide,
(1S,4S)—N-(3′-cyano-[1,1′-biphenyl]-3-yl)-5-(quinolin-2-ylmethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxamide,
(1S,4S)-5-(1,1′-bipheny] 3-ylmethy-N-(3′-cyano-[1,1′bipheny]-3-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxamide,
(1S,4S)—N-(3-bromophenyl)-5-(quinolin-2-ylmethyl)-2,5-diazabicyclo[2.2.1] heptane-2-carboxamide,
(4-phenyl-1H-imidazol-1-yl)((1S,4S)-5-(pyridin-2-yl)-2,5-diazabicyclo[2.2.1] heptan-2-yl)methanone,
((1S,4S)-5-(3-fluorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)(4-phenyl-1H-imidazol-1-yl)methanone,
((1S,4S)-5-(3-(benzyloxy)phenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)(4-phenyl-1H-imidazol-1-yl)methanone,
((1S,4S)-5-([1,1′-biphenyl]-3-ylmethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)(4-phenyl-1H-imidazol-1-yl)methanone,
((1S,4S)-5-([1,1′-biphenyl]-3-ylmethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)(4-bromo-1H-imidazol-1-yl)methanone, and
phenyl (1S,4S)-5-([1,1′,-biphenyl]-3-ylmethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate.

### Claim at position 18

19-20. (canceled)

### Claim 21 (depends on 1)

A method for modulating the activity of FAAH, MAGL or dual FAAH/MAGL which comprises contacting a receptor thereof with an effective amount of a compound of claim 1.

### Claim at position 20

22-24. (canceled)

### Claim 25 (depends on 1)

A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of claim 1.
